At its July 2026 meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) requested that the Department undertake a rapid review of PBS-listed RRMS treatments. The review will consider how RRMS treatments are being used on the PBS and whether the listings remain contemporary with clinical guidelines and evidence.
Further information on this review, including scope, indicative timelines, and consultation processes is available on the Rapid review of PBS medicines for relapsing-remitting multiple sclerosis (RRMS) website. A Utilisation analysis of PBS-listed RRMS medicines is also available.